Today: 21 May 2026
Bloom Energy stock jumps 14% to start 2026 as fuel-cell names rebound — what investors watch next
4 January 2026
2 mins read

Bloom Energy stock jumps 14% to start 2026 as fuel-cell names rebound — what investors watch next

New York, Jan 3, 2026, 19:05 ET — Market closed

  • Bloom Energy (NYSE: BE) surged 13.6% in Friday’s session to close at $98.69.
  • Fuel-cell peers Plug Power and FuelCell Energy also logged double-digit gains.
  • Investors head into Monday watching U.S. jobs data due Jan. 9 and inflation data due Jan. 13 for fresh rate signals.

Bloom Energy Corporation shares jumped 13.6% on Friday, ending the first trading day of 2026 at $98.69 after a volatile session that saw the stock dip below $89 before reversing higher.

The move matters because investors are reopening risk budgets after year-end positioning, with markets bracing for a heavy run of U.S. economic releases that can reshape interest-rate expectations and swing high-beta “energy transition” trades. Reuters

“The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak, in a Reuters report previewing next week’s catalysts. Reuters

Bloom’s rally also comes as traders continue to favor power-related companies tied to data centers, a theme that has lifted a broad set of “AI infrastructure” stocks as grid constraints tighten in parts of the U.S. Reuters

On Friday, Bloom opened at $90.57, traded as high as $98.85 and as low as $88.86, and finished with about 11.6 million shares changing hands — roughly double the prior session’s volume.

Investors have also been digesting Bloom’s late-December disclosure of new financing capacity. The company said in a Dec. 23 filing it entered a $600 million senior secured multicurrency revolving credit facility — a credit line it can draw and repay repeatedly — with Wells Fargo as administrative agent.

The facility matures in December 2030 and can be used for working capital, capital expenditures and permitted acquisitions, as well as other general corporate purposes, the filing showed. The interest rate is linked to SOFR, a benchmark U.S. overnight funding rate, plus a margin tied to leverage.

Bloom’s strength tracked a broader bounce in fuel-cell and hydrogen-linked stocks. Plug Power rose 13.2% to $2.23 and FuelCell Energy gained 11.8% to $8.17 on Friday, according to MarketWatch.

Fuel cells generate electricity through a chemical reaction rather than combustion, which can allow on-site power with different emissions profiles depending on the fuel used — a selling point for customers looking for resilient generation alongside or independent of the grid.

The broader market ended mixed on Friday, with the S&P 500 up 0.19% and the Nasdaq edging down 0.03%, as investors weighed higher Treasury yields and the outlook for U.S. monetary policy.

Before the next session, traders will be watching next week’s U.S. calendar, including manufacturing and services activity data and labor-market releases ahead of the monthly employment report due Jan. 9, Reuters reported.

Inflation will also stay in focus, with the U.S. consumer price index due Jan. 13, while fourth-quarter earnings season ramps up the same week, led by major bank results, Reuters reported.

For Bloom specifically, the next major catalyst is its next earnings update; the company has not confirmed the reporting date, and market calendars currently point to an early-to-late February window.

From a technical perspective, Friday’s low near $88.86 is the closest near-term support, while the $99–$100 area is the first resistance after the sharp reversal. Bloom’s 52-week range sits roughly between $15.15 and $147.86, underscoring the stock’s volatility heading into 2026.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AAOI stock jumps 14% to start 2026 as Applied Optoelectronics rides AI data-center demand
Previous Story

AAOI stock jumps 14% to start 2026 as Applied Optoelectronics rides AI data-center demand

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Next Story

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Go toTop